CG
SPRO icon

Cutler Group’s Spero Therapeutics SPRO Stock Holding History

Cutler Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,200
Closed -$3K – 6299
2021
Q1 		$3K Sell
2,200
-800
-27% -$14.1K ﹤0.01% 4762
2020
Q4 		$3K Sell
3,000
-800
-21% -$12.5K ﹤0.01% 4013
2020
Q3 		$3K Buy
+3,800
New +$45K ﹤0.01% 3895

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cutler Group's SPRO Position: Q4 2021 in Review

Cutler Group sold out of Spero Therapeutics (SPRO) in Q4 2021, closing a stake of 1,260 shares — an estimated $23K sold.

Cutler Group first reported a position in SPRO in Q2 2020 and held it in 5 quarters. The position peaked at $28K in Q2 2021. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • Cutler Group reported no remaining Spero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 1,260 Spero Therapeutics shares in Q4 2021, an estimated $23K.
  • Cutler Group first reported a position in Spero Therapeutics in Q2 2020 and held it in 5 quarters.
  • Cutler Group's Spero Therapeutics position peaked at $28K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.